Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 5/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371292 | 0.80 | BCHE (0.41) | RIPK1HTR2A | |
| SCHEMBL6375541 | 0.79 | KDM4E (0.34) | RIPK1 | |
| SCHEMBL7135441 | 0.79 | ELANE (0.41) | RIPK1HTR2A | |
| SCHEMBL6376107 | 0.73 | KDM4E (0.36) | RIPK1 | |
| SCHEMBL321645 | 0.70 | ALDH1A1 (0.54) | RIPK1CHRNA7CYP19A1TYRHTR2A | |
| SCHEMBL6103526 | 0.69 | CYP1A2 (0.43) | RIPK1 | |
| SCHEMBL7463984 | 0.68 | ESRRG (0.43) | PKM | |
| SCHEMBL4717936 | 0.68 | TSHR (0.45) | RIPK1 | |
| SCHEMBL11452194 | 0.68 | AKR1B1 (0.41) | — | |
| SCHEMBL310196 | 0.68 | CHRNA7 (0.50) | CHRNA7TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071650-B2 | Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea | PACIFIC CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | SUH YOUNG G | 2008-03-13 | — | — | US | disclosed |
| EP-1303483-A4 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORP (KR) | 2004-11-03 | — | — | EP | disclosed |
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-08-14 | — | — | US | disclosed |
| EP-1303483-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002016318-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TAS2R40, TAS1R2, TAS2R45 | RIPK1 2718/4885CHRNA7 1375/4885CYP19A1 3456/4885 |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TAS2R5 | RIPK1 3368/4885CHRNA7 1016/4885CYP19A1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.